Online inquiry

IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12392MR)

This product GTTS-WQ12392MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets SAA1 gene. The antibody can be applied in AA amyloidosis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_000331.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6288
UniProt ID P0DJI8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ12392MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15246MR IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA TAK-079
GTTS-WQ8397MR IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HS006
GTTS-WQ5777MR IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA cetuximab-IR700
GTTS-WQ5675MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CDX-011 (DOX)
GTTS-WQ873MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABBV-176
GTTS-WQ11841MR IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MK-4280
GTTS-WQ3179MR IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ARENEGYR
GTTS-WQ4098MR IVTScrip™ mRNA-Anti-oxLDL, BI-204(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BI-204
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW